Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

480 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-10-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical trial to study the effects of dosage, infusion methods and complications of unfractionated heparin (UFH) treating acute progressive cerebral infraction was conducted. In this study, we observed the effects of four UFH treatments on 480 acute progressive cerebral infraction patients during from the 6th and the 72nd hour after the attack. It was concluded that the ultra-slow continuous intravenous infusion of UFH can significantly reduce the neurological deficit score of patients with progressive cerebral infarction, increase the cure rate, decrease the recurrence rate, and improve long-term quality of daily life. It is more effective than the treatment of intravenous infusion of low- molecular- weight UFH at once a day, and the risk of bleeding may not necessarily be increased.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Minimally Invasive Intracranial Hematoma Aspiration for Spontaneous Intracerebral Hemorrhage

NCT06429553

Spontaneous Cerebral Hemorrhage

RECRUITING NA

The Effect of Huperzine A Injection on Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage: a Pilot Study

NCT05560373

Postoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid Hemorrhage

UNKNOWN PHASE4

The Use of Low Molecular Weight Heparin in Traumatic Brain Injury

NCT00170378

Brain Injury Venous Thrombosis

COMPLETED PHASE4

No Cases of Delayed Intracranial Hemorrhage (d-ICH) Among Patients With Mild Traumatic Brain Injury (mTBI) on Oral Anticoagulation Therapy

NCT05609734

Traumatic Intracranial Hemorrhage Traumatic Brain Injury

COMPLETED

Tranexamic Acid with Intensive Blood Pressure Management in Ultra-Early Intracerebral Hemorrhage

NCT06760078

Spontaneous Intracranial Hemorrhage Hypertension

NOT_YET_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Treatment' effectiveness rates of the four groups were 95.80%, 85.22%, 85.47%, and 87.72% respectively. The result of Group A was significantly different from those of Group B, C, and D (p \<0.05). The adverse complication occurrence rates of the four groups were 5.88%, 3.48%, 4.27% and 3.51%.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heparin Causing Adverse Effects in Therapeutic Use Heparin-induced Thrombosis Acute Cerebral Ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

UFH,once a day

No interventions assigned to this group

heparin Calcium,every 12 hours

No interventions assigned to this group

dextran,Salviae,once a day

No interventions assigned to this group

UFH,continuous intravenous infusion,

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Time after breakout: 6- 72 hours
* Blood pressure: below 180/100 mm Hg (1 mm Hg= 0.133 kPa)
* Paralyzed limb muscle strength: Level 0
* Being conscious or in mild or moderate coma, and hernia- free
* The nerve function continued to aggravate from several hours to a week after the breakout.
* No abnormal blood coagulation Platelet count Plt \>10×109/L
* Brain CT or MRI confirming and ruling out the occurrence of bleeding
* Match the diagnostic standards of acute cerebral infraction established by the 4th Chinese China Neurology Association
* Informed consent Agreement Signed

Exclusion Criteria

* History of intracranial hemorrhage bleeding risk or Plt \<10 × 109/ L
* Record of severe heart, liver, or renal insufficiency or severe diabetes mellitus
* Infarct area larger than 1/3 of hemispheric area
* Pregnant

Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No